Related Experiment Video
Updated: May 2, 2026
A Step by Step Protocol for Subretinal Surgery in Rabbits
Published on: September 13, 2016
[GM6001 suppresses scar formation after glaucoma filtration surgery in rabbits]
1Department of Ophthalmology, Zhujiang Hospital, Southem Medical University, Guangzhou 510282, China.E-mail: shenying_abc@sohu.com.
Objective:
To study the effect of matrix metalloproteinases inhibitor GM6001 in suppressing scar tissue formation in the filtering passage after glaucoma filtration surgery.
Methods:
Twenty-four pigmented rabbits (48 eyes) underwent trabeculectomy followed by subconjunctival injection of GM6001 in the right eye (treated eyes) and injection of PBS in the left eye (control) once a day. The intraocular pressure was monitored postoperatively and proliferating cell nuclear antigen (PCNA)- and α-smooth muscle actin (α-SMA)-positive cells in the filtering pathway were detected using immunohistochemistry.
Results:
On postoperative days 7, 14, 21, and 28, the intraocular pressure was significantly lower in the treated eyes (GM6001) than in the control eyes (P<0.01). The counts of PCNA- and α-SMA-positive cells were also significantly lowered in the treated than in the control eyes (P<0.01).
Conclusion:
GM6001 can inhibit excessive proliferation of the fibroblasts in the filtering pathway to suppress scar tissue formation and prolong the existence of the functional filtration bleb in rabbits.
Insights
Matrix metalloproteinases inhibitor GM6001 significantly reduced scar tissue formation and lowered intraocular pressure after glaucoma surgery in rabbits.
Area of Science:
- Ophthalmology
- Pharmacology
- Cell Biology
Context:
- Glaucoma filtration surgery aims to reduce intraocular pressure.
- Scar tissue formation can impede surgical success.
- Matrix metalloproteinases play a role in tissue remodeling.
Purpose:
- To investigate the efficacy of GM6001, a matrix metalloproteinases inhibitor, in preventing scar tissue formation post-glaucoma filtration surgery.
- To assess the impact of GM6001 on intraocular pressure and cellular proliferation in the filtering pathway.
Summary:
- Trabeculectomy was performed on rabbits, followed by daily subconjunctival injections of GM6001 or PBS.
- Intraocular pressure was monitored, and the expression of proliferating cell nuclear antigen (PCNA) and α-smooth muscle actin (α-SMA) was evaluated.
- GM6001 treatment resulted in significantly lower intraocular pressure and reduced PCNA- and α-SMA-positive cells compared to controls.
Impact:
- GM6001 effectively suppresses fibroblast proliferation and scar tissue formation in the filtering pathway.
- This inhibition prolongs the patency of the filtration bleb, potentially improving long-term surgical outcomes in glaucoma.
- The findings suggest GM6001 as a potential therapeutic agent to enhance glaucoma surgery success.
More Related Videos
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment